Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02257580 · ClinicalTrials.gov registry record · Phase 4
The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO
A Phase 4 study, sponsored by Hospital for Special Surgery, New York.
- Completed
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
NCT02257580 is a Phase 4 study that has completed, run by Hospital for Special Surgery, New York. The registered enrollment target is 28 participants.
The verdict
NCT02257580, a Phase 4 study, has completed, sponsored by Hospital for Special Surgery, New York.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
Study Summary
E-Aminocaproic acid (EACA) is an anti-fibrinolytic agent that is used to decrease blood loss and transfusion requirements after several orthopedic procedures. The aim of this prospective double-blind placebo-controlled randomized trial is to determine whether IV EACA reduces intra-operative calculated total blood loss in patients undergoing bilateral varus rotational osteotomy (VRO). This study will also investigate intraoperative cell saver utilization, transfusion of allogeneic blood, hospital length-of-stay (LOS), short term complications, and long-term outcomes.This study will provide Level I evidence and has the potential to improve outcomes in children undergoing this procedure.
Interventions
- DRUG E-Aminocaproic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-04-01 |
| Est. Completion | 2020-10-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02257580
The ClinicalTrials.gov registry entry for NCT02257580 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hospital for Special Surgery, New York, which has 194 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which E-Aminocaproic acid is the first listed.
NCT02257580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02257580 about?
NCT02257580 is a clinical study titled "The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO". E-Aminocaproic acid (EACA) is an anti-fibrinolytic agent that is used to decrease blood loss and transfusion requirements after several orthopedic procedures. The aim of this prospective double-blind placebo-controlled randomized trial is to determine whether IV EACA reduces intra-operative calculat...
What is the current status of trial NCT02257580?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2015-04-01. Estimated completion is 2020-10-26.
What interventions are being tested in trial NCT02257580?
The interventions under investigation include: E-Aminocaproic acid (DRUG).
Who is sponsoring clinical trial NCT02257580?
This trial is sponsored by Hospital for Special Surgery, New York, which has 194 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.